和鉑醫藥控股有限公司

HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 02142)

VOLUNTARY ANNOUNCEMENT POSITIVE TOPLINE RESULTS FROM PHASE III TRIAL OF BATOCLIMAB (HBM9161) FOR TREATMENT OF GENERALIZED MYASTHENIA GRAVIS

This announcement is made by HBM Holdings Limited (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce positive topline results of its Phase III clinical trial (the "**Phase III Trial**") of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis ("**gMG**").

This pivotal clinical study aimed to confirm the efficacy and safety of batoclimab (HBM9161) in patients with gMG in China. It is a subsequent milestone to the positive outcome of the proof-of-concept study for the treatment of Chinese gMG patients completed in August 2021.

Result from the Phase III Trial met primary endpoint as well as key secondary endpoints. Meanwhile, batoclimab treatment was overall safe and well-tolerated, no new safety signal was identified. Batoclimab is the first anti-FcRn treatment confirmed efficacious and safe in Chinese gMG population. This is also the first positive pivotal trial outcome for batoclimab worldwide.

Batoclimab (HBM9161) is a product to treat multiple pathogenic-IgG mediated autoimmune diseases with significant unmet medical needs. gMG is among the first of such multiple indications and this therapy received the "Breakthrough Therapy Certificate" from NMPA in early 2021. In October 2022, the Company entered into an agreement with NBP Pharma, a wholly owned subsidiary of the CSPC Group, to co-develop batoclimab in Greater China. The Company was responsible for designing and executing the entire clinical trial of batoclimab for gMG in China.

About Batoclimab (HBM9161)

Batoclimab is designed as a fully human monoclonal antibody that selectively binds to and inhibits the neonatal FcRn. FcRn plays a pivotal role in preventing the degradation of IgG antibodies. High levels of pathogenic IgG antibodies drive many autoimmune diseases. As the clinically most advanced FcRn inhibitor being developed in Greater China, batoclimab has potential to be a breakthrough treatment for a wide spectrum of autoimmune diseases in Greater China. The Company is developing batoclimab in Greater China with an initial focus on myasthenia gravis (MG), immune thrombocytopenia (ITP), neuromyelitis optical spectrum disorder (NMOSD), Thyroid Eye Disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and pemphigus vulgaris (PV).

Cautionary Statement: We cannot guarantee that we will be able to successfully develop or ultimately market any of our products referenced in this announcement. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 6 March 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Mr. Yu Min Qiu, Mr. Junfeng Wang and Ms. Weiwei Chen as non-executive Directors; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Mr. Ka Chi Yau as independent non-executive Directors.